AIM: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats. METHODS: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area. RESULTS: In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann-Whitney U test). CONCLUSION: Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.
AIM: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats. METHODS:Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area. RESULTS: In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann-Whitney U test). CONCLUSION: Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.
Authors: Christopher Kiss; Stephan Michels; Franz Prager; Günther Weigert; Wolfgang Geitzenauer; Ursula Schmidt-Erfurth Journal: Retina Date: 2006-10 Impact factor: 4.256
Authors: Andrew A Moshfeghi; Philip J Rosenfeld; Carmen A Puliafito; Stephan Michels; Erin N Marcus; Joshua D Lenchus; Anna S Venkatraman Journal: Ophthalmology Date: 2006-10-05 Impact factor: 12.079
Authors: Robert L Avery; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust Journal: Ophthalmology Date: 2006-02-03 Impact factor: 12.079
Authors: Mohammad H Dastjerdi; Zahra Sadrai; Daniel R Saban; Qiang Zhang; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2011-11-07 Impact factor: 4.799
Authors: Carolyn K Pan; Chandrasekar Durairaj; Uday B Kompella; Ogechi Agwu; Scott C N Oliver; Hugo Quiroz-Mercado; Naresh Mandava; Jeffrey L Olson Journal: J Ocul Pharmacol Ther Date: 2011-05-16 Impact factor: 2.671
Authors: Olga Dratviman-Storobinsky; Bat-Chen R Avraham-Lubin; Murat Hasanreisoglu; Nitza Goldenberg-Cohen Journal: Mol Vis Date: 2009-11-13 Impact factor: 2.367